TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients (age ≥ 18 years) with hyponatremia (\<133mmol/l) due to chronic (\>72h) SIADH defined as~* serum osmolality \<275mosm/kg~* urine osmolality \>100mosm/kg~* urine sodium \>30mmol/l~Exclusion Criteria:~* acute (\<72h) or transient hyponatremia~* severe symptomatic hyponatremia in need of hospital treatment~* diabetes mellitus type 1~* uncontrolled hypothyroidism~* uncontrolled adrenal insufficiency~* renal impairment (GFR \<45ml/min)~* cardiac failure~* symptomatic liver disease / severe hepatic impairment (ALAT / aspartate transaminase (ASAT) \> 3x upper limit)~* treatment with SGLT 2 inhibitors, lithium chloride, urea or glitazone~* severe immunosuppression~* pregnancy or breastfeeding~* palliative situation (end of life care)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Treatment with empagliflozin 25mg tablets once daily for 28 days
- Placebo (Type: PLACEBO_COMPARATOR): Treatment with Placebo tablets once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects chronically infected with HCV genotype 1~* HCV RNA ≥ 10,000 IU/mL at screening~* Treatment-naïve subjects with no previous exposure to an interferon formulation (ie, IFNα, pegIFNα), RBV, or HCV DAA (protease, polymerase inhibitor, etc.)~* Treatment-experienced subjects are eligible~Exclusion Criteria:~* Evidence of cirrhosis~* Liver or any other organ transplant~* Current or known history of cancer within 5 years prior to enrollment~* Documented or suspected HCC~* Evidence of decompensated liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A 1: DCV/ASV/BMS-791325 in treatment-naive subjects (Type: EXPERIMENTAL): Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
- A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects (Type: EXPERIMENTAL): Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject must give written informed consent prior to any study related activities~* Subject age must be between 18 and 55 (both included)~* The subject must have MS according to McDonald criteria~* The subject must have disability equivalent to EDSS of 5.5 or less~* The subject must have been treated with any IFN-β preparation for at least 12 months at any time~* The subject must have been shown to be NAb positive and without no in vivo mRNA MxA response within the last 12 months~* The subject must be prepared and considered able to follow the protocol~Exclusion Criteria:~* The subject must not have conditions that might give rise to similar symptoms as MS~* The subject must not have received any immunomodulatory or immunosuppressive treatment (other than IFN-β or glatiramer acetate) 6 months prior to the screening visit~* The subject must not have received mitoxantrone, cyclophosphamide, treosulphane, natalizumab, daclizumab, rituximab, alemtuzumab, cladribine, or any experimental therapy at any time~* The subject must not have undergone previous total body irradiation, total lymphoid irradiation, stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.~* The subject must not have received treatment with glucocorticoids or ATCH later than 2 month prior to the screening visit~* The subject must not have alcohol and drug dependency~* The subject must not have cardiac or renal insufficiency~* The subject must not have any systemic disease that can influence the subject's safety or compliance~* Subjects may be male or female. Women of child-bearing potential must be sexually inactive or practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, long-acting injectable contraceptive, or double-barrier method (condom or IUD with spermicide)~* The subject must not have known or suspected allergy to IFN-α~* The subject must not have participated in any other study within 3 months prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- IFN-alfa (Type: EXPERIMENTAL): One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
- Interferon-beta (Type: EXPERIMENTAL): One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cervical dystonia with at least 18 months since onset, and previously untreated with botulinum toxin or previously treated with botulinum toxin type A or B with a minimum interval of 16 weeks since the last injection and having returned at least to their usual pre-treatment status~* TWSTRS severity, disability and total scores meeting the defined criteria at baseline~Exclusion Criteria:~* Pure anterocollis or pure retrocollis~* In apparent remission from cervical dystonia~* Previous poor response to the last two botulinum toxin type A or type B treatments~* Being treated with type B toxin due to lack of efficacy to type A toxin or have known neutralizing antibodies to type A toxin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug: abobotulinumtoxinA (Dysport®)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults 30 - 70 years old~2. BMI: 20 - 37 kg/m2~3. Without diabetes as defined by fasting plasma glucose \<126 mg/dL and not taking glucose lowering medications~4. Eligible for statin therapy for primary prevention of ASCVD based on LDL-C ≥ 130 mg/dL, \> 5% ASCVD risk over 10 years, or hs-CRP ≥ 2.0 mg/L~Exclusion Criteria:~1. Younger than 30 or older than 70 years~2. Persons with any significant co-morbidities, such as diabetes (fasting glucose ≥ 126 mg/dL or use of glucose lowering medications), active coronary artery disease, heart failure, accelerated or malignant hypertension, kidney disease (creatinine ≥ 1.5 mg/dL), liver disease (alanine aminotransferase \> 2 times upper limit of normal), or severe anemia (hematocrit \< 30%).~3. Individuals taking any medications for weight loss or known to influence insulin sensitivity.~4. Pregnant or lactating~5. Women unwilling to use an effective birth control method~6. History of statin intolerance

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Individuals without diabetes eligible to receive statin therapy (Type: OTHER): Eligible participants will receive 40 mg of atorvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of hCG on Receptivity of the Human Endometrium

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. between the ages of 18-34 years old~2. successfully applied for oocyte donor status at the Investigators Infertility clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525)~3. meet the ASRM criteria for oocyte donation~Exclusion Criteria:~1. younger than 18 years old or older than 34 years old~2. have not successfully applied for oocyte donor status at the Investigators Infertility clinic (The Fertility Center, 3230 Eagle Park Drive NE, suite 100. Grand Rapids MI 49525)~3. do not meet the ASRM criteria for oocyte donation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 34 Years
- Healthy Volunteers: t

Study Arms:
- Drug: human chorionic gonadotropin (hCG) (Type: EXPERIMENTAL): Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis.
- IVF media (Global-trademark) (Type: PLACEBO_COMPARATOR): Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with seasonal allergic rhinitis~Exclusion Criteria:~* Patients who have nasal diseases (e.g., nasal polyp, septonasal arcuation, hypertrophic rhinitis), upper respiratory infection, sinusitis, infectious rhinitis, ocular infection and those disease severe enough to interfere with assessment of effectiveness~* Patients who have rhinitis medicamentosa, or nonallergic rhinitis (e.g., vasomotor rhinitis, eosinophilia rhinitis)~* Patient has a disease of the cardiovascular, hepatic, renal, hematologic systems, or other severe disease

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Intake of Finger-food on Elderly People in Seniors's Resident

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents institutionalized in seniors's resident for 3 months at least~* Residents in disability to feed single-handedly because of cognitive and/or physical disorders~* Having at least use of a hand~* Do not opposing the participation in the study or information and not opposition of the family / close to confidence / legal guardian in case of resident in incapacity to understand (senility, insanity)~Exclusion Criteria:~* Confined to bed~* Specific diets (without residue, allergen, ...)~* Enteral nutrition~* Absence motricity of 2 hands

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutrition with Finger-Food (Type: EXPERIMENTAL): Nutrition with Finger-Food
- Nutrition without Finger-Food (Type: ACTIVE_COMPARATOR): Nutrition without Finger-Food

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVEF \< 40% (by any imaging modality: echocardiography/SPECT/LV angiography)~* A history of Q-wave MI with a residual akinetic and nonviable scar (as evidenced by low-dose dobutamine stress echocardiogram and/or or thallium redistribution nuclear study for viability and/or an electrocardiogram)~* Patients scheduled for surgical revascularization within few days (\< 2 weeks) of the initial screening~Exclusion Criteria:~* Age \>75 by time of infusion~* Cardiogenic shock~* Severe co-morbidities (e.g., renal failure, liver failure)~* Mini-CABG procedures~* Pregnant/nursing women or women of child-bearing potential~* Inability to provide informed consent~* Diabetic Hgb A1c \> 8.5%~* Patients with a history of hepatitis B, hepatitis C, and HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
- Control group (Type: NO_INTERVENTION): Patients in this arm did not receive any intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30-80 years old~* Documented history of type 2 diabetes~* Stable angiotensin converting enzyme/angiotensin receptor blocker (ACE/ARB) regimen 30 days before and throughout the study period~* Stable anti-diabetic regimen throughout the study period~* Body mass index (BMI) between 22-45 kg/m2~* HbA1c between 6-9% for patients on anti-diabetic treatment regimen and HbA1c between 6-8% for patients who are being controlled by diet alone~* Screening blood pressure (BP) \> 130/80 (average of 3 sitting measurements), with current medications~Exclusion Criteria:~* Uncontrollable or symptomatic arrhythmias~* Unstable angina~* Sick sinus syndrome or second or third degree heart block~* Decompensated heart failure~* Myocardial infarction (MI) or stroke within 3 months of screening~* Bradycardia~* Chronic obstructive pulmonary disease (COPD) with required inhaled or oral bronchodilators or corticosteroids~* Bronchial asthma or related bronchospastic conditions~* New onset/diagnosed type 2 diabetes (\<3 months)~* Clinically significant renal or liver disease (creatinine \>2.5 mg/dL)~* Endocrine disorders~* Use of anorectic or other diet drugs inconsistent with recommendations for type 2 diabetics~* Use of beta-blockers within 3 months of screening~* Use of corticosteroids~* Systemic disease, including cancer, with reduced life expectancy (\<12 months)~* Psychological illness/condition that interferes with comprehension of study requirements~* Use of an investigational drug within 30 days of entry into study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol (Type: EXPERIMENTAL): Carvedilol, orally, 25 mg, twice daily for five months
- Metoprolol (Type: ACTIVE_COMPARATOR): Metoprolol, orally, 200 mg, twice daily for five months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons aged 15 - 65 years old~* Presenting with mild to moderate, non-bloody, acute diarrhea (≥3 loose stools/day for \<3 days) to participating health care settings~* For whom the study physicians recommend antimicrobial treatment~Exclusion Criteria:~* Is pregnant~* Requires hospitalization~* Has signs or symptoms of septicemia~* Has a primary complaint of another acute illness~* Has a serious chronic illness~* Has an allergy to aspirin~* Has been exposed to antimicrobial or antidiarrheal medications within 72 hours of enrollment~* Previously enrolled in study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Bismuth subsalicylate (Type: EXPERIMENTAL): Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: At least 2 years (at time of obtaining informed consent)~* Diagnosis of AD based on the Japanese Dermatological Association's criteria~* Atopic dermatitis affecting ≥5% of body surface area (BSA, excluding scalp) at the screening and baseline examinations~Exclusion Criteria:~- Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.3% OPA-15406 ointment (Type: EXPERIMENTAL): Twice daily
- 1% OPA-15406 ointment (Type: EXPERIMENTAL): Twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects with eGFR between 25-65 mL/min/1.73m2 (if aged 18 to55) or eGFR between 25-44 mL/min/1.73m2 (if aged 56 to \<66)~* Tolvaptan naïve~* Diagnosis of ADPKD by modified pei-Ravine criteria 1) 3 cysts per kidney by sonography or 5 cysts by CT or MRI with family history of ADPKD or 2) 10 cysts per kidney by any radiologic method and exclusion of other cystic kidney diseases if without family history~Exclusion Criteria:~* Women of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of Investigational medicinal product (IMP)~* Women who are breast-feeding and/or who have a positive pregnancy test prior to receiving IMP~* Need for chronic diuretic use~* Hepatic impairment or liver function abnormalities other than that expected for ADPKD with typical cystic liver disease~* Advanced diabetes, evidence of additional significant renal disease, renal cancer, single kidney, recent renal surgery or acute kidney injury~* Contraindications to required trial assessments~* Medical history or medical findings inconsistent with safety or compliance with trial assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Tolvaptan (OPC-41061)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete